{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:13:20Z","timestamp":1794557600206,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Concerns about the safety and efficacy of vaccines in patients with autoimmune diseases (AID) have led to contradictions and low vaccination coverage in this population, who are at a higher risk of infections, including by human papillomavirus (HPV). Although HPV vaccines have been recommended for immunocompromised patients, there is still a lack of data to support its use for AID patients, such as juvenile dermatomyositis (JDM) patients. The aim of this study was to assess the safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine in a cohort of JDM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>JDM patients aged from 9 to 20\u2009years and healthy controls (HC) were enrolled to receive a 3-dose schedule of qHPV vaccine from March\/2014 to March\/2016. Study visits were performed before the first dose, 1\u2009month after the second and third doses, and 6\u2009months after the third dose. Participants completed a diary of possible adverse events for 14\u2009days following each dose of vaccination (AEFV). Disease activity and current therapy were analyzed at each visit for JDM patients. In addition, serum samples from all participants were collected to test antibody concentrations against HPV16 and 18 at each visit. Participant recruitment was conducted in ten Brazilian centres. From 47 eligible JDM patients and 41 HC, 42 and 35, respectively, completed the 3-dose schedule of the vaccine, given that five JDM patients and two HC had received doses prior to their inclusion in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The AEFVs presented by the participants were mild and in general did not differ between JDM and HC groups. No severe AEFVs were related to the vaccination. Disease activity was stable, or even improved during the follow-up. One month after the third dose of the vaccine the JDM group presented seropositivity of 100% for HPV16 and 97% for HPV18, similarly to the HC group, who presented 100% for both serotypes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.000). Six months after the third dose the seropositivity for the patient group was 94% for both HPV types.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The HPV vaccination in this cohort of JDM patients was safe and immunogenic. Since the seropositivity against HPV16 and 18 was very high after the 3-dose schedule, this regimen should be recommended for JDM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Brazilian Clinical Trials Registry, number:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ensaiosclinicos.gov.br\/rg\/RBR-9ypbtf\/\">RBR-9ypbtf<\/jats:ext-link>\n                      . Registered 20 March 2018 \u2013 Retrospectively registered.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-020-00479-w","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T09:03:09Z","timestamp":1605085389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2290-5906","authenticated-orcid":false,"given":"Ingrid Herta Rotstein","family":"Grein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Balera Ferreira","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noortje","family":"Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Bertini","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Emi","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassia","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Terreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Coelho Moreira","family":"da Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Knupp Feitosa","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Sztajnbok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana B.","family":"Paim Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Garcia","family":"Islab\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Bica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"de Oliveira Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Saad","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virg\u00ednia","family":"Ferriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hella","family":"Pasmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutger","family":"Schepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"van der Klis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gecilmara Salviato","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"479_CR1","doi-asserted-by":"crossref","unstructured":"Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5.","DOI":"10.1136\/rmdopen-2019-001041"},{"key":"479_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"479_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2014.206","volume":"11","author":"J Westra","year":"2015","unstructured":"Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"479_CR4","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","volume":"70","author":"MW Heijstek","year":"2011","unstructured":"Heijstek MW, Bruin LMO, Bijl M, Borrow R, van der Klis F, Kon\u00e9-Paut I, Fasth A, Minden K, Ravelli A, Abinun M, Pileggi GS, Borte M, Wulffraat NM. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70:1704\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"479_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11926-015-0519-y","volume":"17","author":"N Groot","year":"2015","unstructured":"Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;17(7):46.","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"479_CR6","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrrheum.2013.95","volume":"9","author":"CA Silva","year":"2013","unstructured":"Silva CA, Aikawa NE, Bonfa E. Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol. 2013;9(9):532\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"479_CR7","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/ker102","volume":"50","author":"L Dell\u2019Era","year":"2011","unstructured":"Dell\u2019Era L, Esposito S, Corona F, Principi N. Vaccination of children and adolescents with rheumatic diseases. Rheumatology (Oxford). 2011;50:1358\u201365.","journal-title":"Rheumatology (Oxford)"},{"issue":"30","key":"479_CR8","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1016\/j.vaccine.2015.05.041","volume":"33","author":"P Pellegrino","year":"2015","unstructured":"Pellegrino P, Radice S, Clementi E. Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: a systematic review. Vaccine. 2015;33(30):3444\u20139.","journal-title":"Vaccine."},{"key":"479_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12969-016-0072-x","volume":"14","author":"Grein","year":"2016","unstructured":"Grein, et al. HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. Pediatr Rheumatol. 2016;14:12.","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"479_CR10","first-page":"182","volume":"39","author":"G Lube","year":"2014","unstructured":"Lube G, et al. Condyloma acuminatum by human papilloma virus infection in childhood-systemic lupus erythematosus patients. Acta Reumatol Port. 2014;39(2):182\u20137.","journal-title":"Acta Reumatol Port"},{"issue":"2","key":"479_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00296-012-2426-0","volume":"33","author":"LD Lyrio","year":"2013","unstructured":"Lyrio LD, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2):335\u201340.","journal-title":"Rheumatol Int"},{"issue":"5","key":"479_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s10067-010-1606-0","volume":"30","author":"IU Santana","year":"2011","unstructured":"Santana IU, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011;30(5):665\u201372.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"479_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/rheumatology\/keq304","volume":"50","author":"H Liu","year":"2011","unstructured":"Liu H, et al. Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford). 2011;50(2):343\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"479_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00403-019-01913-0)10.1007\/s00403-019-01913-0)","volume":"311","author":"Z Ren","year":"2019","unstructured":"Ren Z, Laumann AE, Silverberg JI. Association of dermatomyositis with systemic and opportunistic infections in the United States. Arch Dermatol Res. 2019;311(5):377\u201387. https:\/\/doi.org\/10.1007\/s00403-019-01913-0)10.1007\/s00403-019-01913-0).","journal-title":"Arch Dermatol Res"},{"key":"479_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.semarthrit.2015.01.002","volume":"44","author":"EF Lawson","year":"2015","unstructured":"Lawson EF, et al. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemiclupus erythematosus. Semin Arthritis Rheum. 2015;44:666\u201371.","journal-title":"Semin Arthritis Rheum"},{"key":"479_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/rheumatology\/keu531","volume":"54","author":"C Hua","year":"2015","unstructured":"Hua C, et al. Reasons for non-vaccination in French rheumatoid arthritis andspondyloarthritis patients. Rheumatology. 2015;54:748\u201350.","journal-title":"Rheumatology"},{"key":"479_CR17","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1093\/rheumatology\/kes175","volume":"51","author":"MP Morin","year":"2012","unstructured":"Morin MP, Quach C, Fortin E, Ch\u00e9deville G. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford). 2012;51:2046\u201350.","journal-title":"Rheumatology (Oxford)"},{"key":"479_CR18","unstructured":"BizjakM et al. Vaccination coverage in children with rheumatic diseases. Clin Exp Rheumatol 2020; 38: 164\u2013170."},{"key":"479_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","volume":"15","author":"M Drolet","year":"2015","unstructured":"Drolet M, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15:565\u201380.","journal-title":"Lancet Infect Dis"},{"key":"479_CR20","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1136\/bmj.c3493","volume":"341","author":"J Dillner","year":"2010","unstructured":"Group FIIS, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four-year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:3493.","journal-title":"BMJ."},{"key":"479_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/jnci\/djp534","volume":"102","author":"N Mu\u00f1oz","year":"2010","unstructured":"Mu\u00f1oz N, et al. Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102:325\u201339.","journal-title":"J Natl Cancer Inst"},{"key":"479_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/INF.0000000000000793","volume":"34","author":"M Vichnin","year":"2015","unstructured":"Vichnin M, et al. An overview of quadrivalent human papillomavirus vaccine safety. Pediatr Infect Dis J. 2015;34:983\u201391.","journal-title":"Pediatr Infect Dis J"},{"key":"479_CR23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s10067-014-2846-1","volume":"34","author":"DA Geier","year":"2015","unstructured":"Geier DA, Geier MR. A case\u2013control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol. 2015;34:1225\u201331.","journal-title":"Clin Rheumatol"},{"key":"479_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/0961203311429556","volume":"21","author":"HF Soldevilla","year":"2012","unstructured":"Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21:158\u201361.","journal-title":"Lupus"},{"issue":"5","key":"479_CR25","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1590\/1414-431x20155060","volume":"49","author":"AF Nicol","year":"2016","unstructured":"Nicol AF, Andrade CV, Russomano FB, Rodrigues LLS, Oliveira NS, Provance DW Jr. HPV vaccines: a controversial issue? Braz J Med Biol Res. 2016;49(5):5060.","journal-title":"Braz J Med Biol Res"},{"key":"479_CR26","doi-asserted-by":"publisher","first-page":"f5906","DOI":"10.1136\/bmj.f5906","volume":"347","author":"L Arnheim-Dahlstr\u00f6m","year":"2013","unstructured":"Arnheim-Dahlstr\u00f6m L, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunization of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.","journal-title":"BMJ"},{"key":"479_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","volume":"271","author":"C Chao","year":"2012","unstructured":"Chao C, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:193\u2013203.","journal-title":"J Intern Med"},{"issue":"92","key":"479_CR28","first-page":"241","volume":"19","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;19(92):241\u201368.","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"479_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.15167\/2421-4248\/jpmh2018.59.3.998","volume":"59","author":"C Genovese","year":"2018","unstructured":"Genovese C, LA Fauci V, Squeri A, Trimarchi G, Squeri R. HPV vaccine and autoimmune diseases: systematic review and meta-analysis of the literature. J Prev Med Hyg. 2018;59(3):194\u20139. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2018.59.3.998.","journal-title":"J Prev Med Hyg"},{"key":"479_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/joim.12535","volume":"280","author":"O Gronlund","year":"2016","unstructured":"Gronlund O, et al. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Intern Med. 2016;280:618\u201326.","journal-title":"J Intern Med"},{"key":"479_CR31","unstructured":"Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis, Coordena\u00e7\u00e3o-geral do Programa Nacional de Imuniza\u00e7\u00f5es. Informe t\u00e9cnico da amplia\u00e7\u00e3o da oferta das vacinas papilomav\u00edrus humano 6, 11, 16 e 18 (recombinante) \u2013 vacina HPV quadrivalente e meningoc\u00f3cica C (conjugada). Brasilia, 2018."},{"key":"479_CR32","unstructured":"World Health Organization Meeting of the Strategic Advisory Group of Experts on Immunization April 2014 \u2013 Conclusions and Recommendations. Wkly Epidemiol Rec. 2014;21(89):221\u2013236."},{"issue":"8","key":"479_CR33","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/annrheumdis-2013-203429","volume":"73","author":"MW Heijstek","year":"2014","unstructured":"Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014;73(8):1500\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"479_CR34","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.3899\/jrheum.130246","volume":"40","author":"MW Heijstek","year":"2013","unstructured":"Heijstek MW, Scherpenisse M, Groot N, Wulffraat NM, van Der Klis FR. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol. 2013;40(9):1626\u20137.","journal-title":"J Rheumatol"},{"issue":"7","key":"479_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and Dermatomyositis. N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"key":"479_CR36","unstructured":"Immunization Safety Surveillance: Guidelines for Immunization Programme Managers on Surveillance of Adverse Events Following Immunization Regional Office for the Western Pacific Region. World Health Organization. Manila: WHO Press; 2013."},{"issue":"10","key":"479_CR37","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8","volume":"42","author":"DJ Lovell","year":"1999","unstructured":"Lovell DJ, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS). Arthritis Rheum. 1999;42(10):2213\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"479_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient\/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)\/childhood health assessment. Arthritis Care Res. 2011;63(11):118\u201357.","journal-title":"Arthritis Care Res"},{"key":"479_CR39","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","volume":"72","author":"D Lazarevic","year":"2013","unstructured":"Lazarevic D, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;72:686\u201393.","journal-title":"Ann Rheum Dis"},{"key":"479_CR40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"Rider LG, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14:303\u201318.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"479_CR41","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/acr.20280","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, et al. (PRINTO and PRCSG). The paediatric rheumatology international trials organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res. 2010;62(11):1533\u201341.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"479_CR42","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","volume":"72","author":"CC Mok","year":"2013","unstructured":"Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659\u201364.","journal-title":"Ann Rheum Dis"},{"key":"479_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1546-0096-11-29","volume":"11","author":"A Soybilgic","year":"2013","unstructured":"Soybilgic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013;11:29.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"20","key":"479_CR44","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1016\/j.vaccine.2017.04.001","volume":"35","author":"JP Dhar","year":"2017","unstructured":"Dhar JP, Essenmacher L, Dhar R, Magee A, Ager J, Sokol RJ. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine. 2017;35(20):2642\u20136.","journal-title":"Vaccine."},{"key":"479_CR45","doi-asserted-by":"publisher","unstructured":"Grein, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multicentre study. LUPUS. 2020. https:\/\/doi.org\/10.1177\/0961203320928406.","DOI":"10.1177\/0961203320928406"},{"key":"479_CR46","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1016\/j.vaccine.2018.04.056","volume":"36","author":"CC Mok","year":"2018","unstructured":"Mok CC, Ho LY, To CH. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine. 2018;36:3301\u20137.","journal-title":"Vaccine"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00479-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-020-00479-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00479-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T09:24:50Z","timestamp":1605086690000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-020-00479-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1186\/s12969-020-00479-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22478\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.22478\/v2","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"30 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Human Research Ethics Committee of the Hospital das Cl\u00ednicas de Ribeir\u00e3o Preto and the Ribeir\u00e3o Preto Medical School, SP, Brazil on July 21, 2014.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A copy of the Informed Consent (for parents and legal guardians) and the Informed Consent (for healthy patients and controls) were given to the study participants and their guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest, including financial interests, activities, relationships, and affiliations to be disclosed in relation to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}